ReviewCNS drugs2021
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.
Review in CNS drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Implications of dopaminergic medication withdrawal in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2022Pooled it
- Adult transverse colon intussusception: A case report and literature review.Radiology case reports · 2026Article
- Parkinson's disease: pathogenesis and therapeutic strategies.Molecular biomedicine · 2026Review
- Motor and non-motor fluctuations in Parkinson's disease: the knowns and unknowns of current therapeutic approaches.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Current and emerging drugs for Parkinson's disease: mechanisms, clinical evidence, and future directions.Frontiers in pharmacology · 2026Review
- Beyond Dysphagia in Parkinson's Disease: 3D Printing of Orally Disintegrating Tablets (ODTs) for Optimized Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Electrophysiological Evidence for Impaired Central Pain Modulation in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Safety and efficacy of rotigotine in patients with frontotemporal dementia: a phase 2, double-blind, randomized, placebo-controlled, multicenter trial.The Lancet regional health. Europe · 2025Article
- A Review of the Recent Advances in the Pharmacological Management of Parkinson's Disease.Cureus · 2025Review
- Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data.BMC pharmacology & toxicology · 2025Article
- Development and Characterization of Cannabidiol Gummy Using 3D Printing.Gels (Basel, Switzerland) · 2025Article
- AI-Driven Innovation in Skin Kinetics for Transdermal Drug Delivery: Overcoming Barriers and Enhancing Precision.Pharmaceutics · 2025Review
- Patient-Reported Outcomes of Rotigotine in Parkinson's Disease: Real-World Evidence on Symptom Control and Quality of Life From China.Parkinson's disease · 2025Article
- Effects of rotigotine on sleep in Parkinson's disease patients: a Parkinson's KinetiGraph study.Frontiers in neurology · 2025Article
- Using Polymers as Crystal Inhibitors to Prevent the Crystallization of the Rotigotine Patch.Pharmaceutics · 2024Article
- A liquid crystal in situ gel based on rotigotine for the treatment of Parkinson's disease.Drug delivery and translational research · 2024Article
- Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Effective Management of "OFF" Episodes in Parkinson's Disease: Emerging Treatment Strategies and Unmet Clinical Needs.Neuropsychiatric disease and treatment · 2023Review
- Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson's Disease.Current neuropharmacology · 2023Review
- Potential Therapeutic Transdermal Psychoactive Drug Delivery Technology.ACS medicinal chemistry letters · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motor and non-motor symptoms (NMS) have a substantial effect on the health-related quality of life (QoL) of patients with Parkinson's disease (PD). Transdermal therapy has emerged as a time-tested practical treatment option, and the rotigotine patch has been used worldwide as an alternative to conventional oral treatment for PD. The efficacy of rotigotine on motor aspects of PD, as well as its safety and tolerability profile, are well-established, whereas its effects on a wide range of NMS have been described and studied but are not widely appreciated. In this review, we present our overall experience with rotigotine and its tolerability and make recommendations for its use in PD and restless legs syndrome, with a specific focus on NMS, underpinned by level 1-4 evidence. We believe that the effective use of the rotigotine transdermal patch can address motor symptoms and a wide range of NMS, improving health-related QoL for patients with PD. More specifically, the positive effects of rotigotine on non-motor fluctuations are also relevant. We also discuss the additional advantages of the transdermal application of rotigotine when oral therapy cannot be used, for instance in acute medical emergencies or nil-by-mouth or pre/post-surgical scenarios. We highlight evidence to support the use of rotigotine in selected cases (in addition to general use for motor benefit) in the context of personalised medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.